Statins, a class of medications widely prescribed to lower cholesterol levels and prevent heart disease and stroke, may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a study suggests. The study, “Screening for YAP Inhibitors Identifies Statins as Modulators of Fibrosis,” was published recently…
The newly founded Pulmonary Wellness Foundation recently launched its interactive online 2020 Lecture Series, covering an array of topics related to respiratory health for patients, caregivers, family members, and clinicians. The free webinars are presented at 7 p.m. EST every Wednesday by the nonprofit and its founder, cardiopulmonary…
Blocking production of the enzyme JNK1 in cells lining the lungs’ airways protected mice from developing induced idiopathic pulmonary fibrosis (IPF), and almost completely reversed tissue fibrosis (scarring) in a mouse model, a study shows. The study, “Airway epithelial specific deletion of Jun-N-terminal kinase 1 attenuates…
Female sex, younger age, and a better lung function at time of diagnosis tend to support a a better overall prognosis among people with idiopathic pulmonary fibrosis (IPF), a large registry-based study reports. In contrast, the presence of pulmonary hypertension (PH), lung cancer,…
The antibiotic azithromycin (AZT), frequently prescribed for fighting bacterial infections, has anti-fibrotic effects and promotes the death of fibroblasts — cells promoting fibrosis, or scarring — in people with idiopathic pulmonary fibrosis (IPF), a new study shows. These findings suggest the potential of AZT as a therapeutic…
The protein peroxiredoxin-4 may be a useful blood marker in the early detection of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF), a study has found. The finding was described in the article “The overexpression of peroxiredoxin-4 affects the progression of idiopathic pulmonary fibrosis,” which was published…
New York cardiopulmonary physical therapist Noah Greenspan has launched the Pulmonary Wellness Foundation (PWF), a nonprofit group that provides free online information on a range of prevalent, rare and ultra-rare pulmonary diseases for those who can’t afford to pay for it. PWF specifically targets patients with pulmonary fibrosis,…
Galapagos NV announced that its Phase 2 PINTA trial, evaluating the safety and effectiveness of oral GLPG1205 in people with idiopathic pulmonary fibrosis (IPF), has completed patient recruitment ahead of schedule. GLPG1205 is a small molecule designed to specifically block the activity of GPR84, a protein that…
Marking a decade of raising funds to battle pulmonary fibrosis (PF), this year’s glitzy and glamorous “Broadway Belts for PFF!” event will be held on Feb. 24 in New York City. Bringing together a host of Broadway stars and other celebrities, the annual evening…
Boehringer Ingelheim has acquired the worldwide exclusive rights to Enleofen‘s interleukin-11 (IL-11) platform, designed for the treatment of fibrotic diseases such as pulmonary fibrosis. This newly established partnership brings together Boehringer Ingelheim’s expertise and substantial pipeline in fibrotic diseases, and Enleofen’s knowledge of IL-11 biology. Enleofen…
Get regular updates to your inbox.
